Panten U, Schwanstecher M, Schwanstecher C
Institut für Pharmakologie und Toxikologie, Universität Göttingen, Germany.
Horm Metab Res. 1992 Dec;24(12):549-54. doi: 10.1055/s-2007-1003387.
The hypoglycemic effect of sulfonylureas and their analogues results from their binding to a high affinity site in the B-cell plasma membrane. This site seems to be a structural component of the ATP-sensitive K(+)-channel and represents the pancreatic sulfonylurea receptor. Binding of sulfonylureas causes closure of the ATP-sensitive K(+)-channel and thereby initiates a chain of events eventually leading to the release of insulin. Diazoxide inhibits insulin secretion via opening of the ATP-sensitive K(+)-channel. Sulfonylurea receptors resembling the pancreatic receptor occur in nerve cells, cardiac muscle, skeletal muscle and smooth muscle. Neither these extrapancreatic receptors nor low affinity receptors for sulfonylureas in myocytes and adipocytes contribute to the therapeutic benefit of sulfonylureas.
磺脲类药物及其类似物的降血糖作用源于它们与B细胞膜中高亲和力位点的结合。该位点似乎是ATP敏感性钾通道的一个结构成分,代表胰腺磺脲类受体。磺脲类药物的结合会导致ATP敏感性钾通道关闭,从而引发一系列最终导致胰岛素释放的事件。二氮嗪通过打开ATP敏感性钾通道来抑制胰岛素分泌。在神经细胞、心肌、骨骼肌和平滑肌中存在类似于胰腺受体的磺脲类受体。这些胰腺外受体以及心肌细胞和脂肪细胞中磺脲类药物的低亲和力受体均未对磺脲类药物的治疗益处产生作用。